GOTHENBURG, Sweden, March 2, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced the appointment of Sijme Zeilemaker as Senior Director Business Development. Mr. Zeilemaker joins Immunicum with a breadth of experience in science-based business transactions and a refined knowledge and understanding of oncology-based biotech companies. He will report to Carlos de Sousa, CEO of Immunicum.
"Sijme's previous experiences in each layer of the business development process and the oncology landscape will greatly contribute to our ability as a leadership team to more actively engage with potential partners, a key aspect of our corporate strategy," said Carlos de Sousa, CEO of Immunicum. "His insight and network of cancer-focused biotechnology companies as well as connections to big pharma will provide the fundamental support needed for Immunicum as we advance our programs and further evolve as a company."
"I am very much looking forward to being an active part of the Immunicum team," said Sijme Zeilemaker. "I truly believe in the great potential of Immunicum's immuno-oncology therapeutic approach and highly appreciate the opportunity to join and support the company in its next stage of development."
Sijme Zeilemaker joins Immunicum having most recently served as Director Business Development at InteRNA Technologies where he supported the preclinical oncology company in connecting with pharmaceutical and biotechnology companies, licensing technologies and exploring grant opportunities. Sijme also served as Head of Business for 2-BBB Medicines and Business Development Manager for to-BBB technologies where he provided partnering support and attracted over €7.5 million in non-dilutive funding. Sijme obtained a Masters degree in Biomedical Sciences from Leiden University, The Netherlands.
About Immunicum AB (publ)
Immunicum AB (First North Premier: IMMU.ST) is a clinical stage company developing novel immuno-oncology therapies against a range of solid tumors. The Company's lead compound, INTUVAX® is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX® was designed to combine the best of two worlds: a cost-effective cell-based (allogeneic) and off-the-shelf therapy that is capable of triggering a highly personalized and potentially long-lasting immune response against tumor cells throughout the body. www.immunicum.com
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Ph: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Media Contact
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Ph: +49 89 2424 3494 or + 49 175 571 1562
E-mail: gschweitzer@macbiocom.com
The Company's Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31
www.redeye.se
The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the company's contact person on March 2, 2017 at 8.00 am CET